By regulating the activity of LPL, these drugs are expected to not only alleviate lipid metabolism disorders but also improve the pro-inflammatory immune environment in the kidneys, reduce persistent tissue damage, and ultimately delay the progression of DKD. The gene discussed is LPL; the disease is Disorder of lipid metabolism.